If you are developing opioid antagonists for therapeutic use, it is important to use non-clinical studies to profile the effects of the compounds at mu, kappa and delta opioid receptors to confirm mode of action and evaluate the potential for adverse side effects associated with agonist activity at opioid receptors.
NMRA-140 is a selective kappa opioid receptor antagonist being developed for the treatment of depression by Neumora Therapeutics.
Filomene Morrison of Neumora Therapeutics will be presenting the following poster at the Annual Meeting of the Society of Biological Psychiatry to be held at the Hilton San Diego Bayfront, San Diego, California, 27th-29th April, 2023.
'NMRA-140, a Novel and Selective Kappa Opioid Receptor Antagonist: Mode of Action Profiling Studies Demonstrate No Opioid Agonist Properties Implicated in Opioid-Related Abuse' Filomene Morrison, Lori Jean Van Orden, Karla Zeitz, David Heal, Sharon Smith, Tanya L. Wallace
This poster was produced in collaboration with two of our consultants (David Heal and Sharon Smith).